|
Status |
Public on Jul 09, 2009 |
Title |
Human MM cell line treated, biological rep1 |
Sample type |
RNA |
|
|
Source name |
Human MM cell line onconase treated
|
Organism |
Homo sapiens |
Characteristics |
cell line: M25 cell type: Human malignant mesothelioma (MM)
|
Treatment protocol |
At ~50 to 80% confluence, all MM cell lines were incubated with Onconase (5 µg/ml, Alfacell) for 24 h in the presence of growth medium containing 10% fetal bovine serum.
|
Growth protocol |
Cells were propagated in 10 cm dishes (Falcon) in RPMI medium containing 10% FBS.
|
Extracted molecule |
total RNA |
Extraction protocol |
Trizol extraction of total RNA was performed according to the manufacturer's instructions.
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 5 ug total RNA (Affymetrix Eukaryote One-Cycle Target Labelling Assay).
|
|
|
Hybridization protocol |
Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on Affymetrix Human Genome U133 plus 2.0 Gene Chips (HG U133 plus 2.0). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
|
Scan protocol |
GeneChips were scanned using the Affymetrix GeneChip Scanner 3000.
|
Description |
Gene expression data from Human MM cell line onconase treated
|
Data processing |
Relative expression values were generated for each transcript using the Affymetrix MAS5.0 algorithm in GeneChip® Operating Software (GCOS) Version 1.4 with All Probe Sets Scaling of 500.
|
|
|
Submission date |
Jul 08, 2009 |
Last update date |
Jul 08, 2009 |
Contact name |
JIANMING PEI |
E-mail(s) |
[email protected]
|
Phone |
2157282898
|
Fax |
2152141623
|
Organization name |
Fox Chase Cancer Center
|
Department |
Population Science
|
Lab |
Testa's Lab
|
Street address |
333 Cottman Ave.
|
City |
Philadelphia |
State/province |
PA |
ZIP/Postal code |
19111 |
Country |
USA |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE17009 |
Onconase Responsive Genes in Human Mesothelioma Cells: Implications for an RNA Damaging Therapeutic Agent |
|